{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-255494","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2022-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.603785+00:00","generated_at":"2026-06-23T06:23:44.171717+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Silverback Therapeutics terminates Seattle HQ lease effective Dec 31, 2022","bullets":["Terminated lease for ~19,829 sq ft at 500 Fairview Ave N, Seattle; lease expires Dec 31, 2022.","No termination fee payable to landlord; lease end contingent on new tenant lease now executed.","Tenant remains responsible for all rent through Dec 31, 2022; must surrender premises in good condition.","Silverback grants temporary license to new tenant (Approved Licensee) for premises before termination.","Company discloses it is undergoing a corporate merger; tenant entity will survive and remain liable."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-255494","json":"https://secwatch.observer/filing/0001193125-22-255494.json","markdown":"https://secwatch.observer/filing/0001193125-22-255494.md","text":"https://secwatch.observer/filing/0001193125-22-255494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/0001193125-22-255494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/d596886d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:23:44.171717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}